Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors,  or both? Expectations from The ONTARGET  Trial Programme

Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors,  or both? Expectations from The ONTARGET  Trial Programme

Luis Miguel  Ruilope1, Josep Redón2, Roland Schmieder31Servicio de Nefrologia, Unidad de Hipertension Hospital, 12 de Octubre, Madrid, Spain; 2Department of Internal Medicine, Hospital Clinico University of Valencia, Valencia, Spain; 3Department of Nephrology and Hypertension, Fr...

Full description

Bibliographic Details
Main Authors: Luis Miguel  Ruilope, Josep Redón, Rol, Schmieder
Format: Article
Language:English
Published: Dove Medical Press 2007-03-01
Series:Vascular Health and Risk Management
Online Access:https://www.dovepress.com/cardiovascular-risk-reduction-by-reversing-endothelial-dysfunction-arb-peer-reviewed-article-VHRM

Internet

https://www.dovepress.com/cardiovascular-risk-reduction-by-reversing-endothelial-dysfunction-arb-peer-reviewed-article-VHRM

Similar Items